JP2014507435A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014507435A5 JP2014507435A5 JP2013553604A JP2013553604A JP2014507435A5 JP 2014507435 A5 JP2014507435 A5 JP 2014507435A5 JP 2013553604 A JP2013553604 A JP 2013553604A JP 2013553604 A JP2013553604 A JP 2013553604A JP 2014507435 A5 JP2014507435 A5 JP 2014507435A5
- Authority
- JP
- Japan
- Prior art keywords
- monoclonal antibody
- antibody
- seq
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 101001044940 Homo sapiens Insulin-like growth factor-binding protein 2 Proteins 0.000 claims 8
- 102100022710 Insulin-like growth factor-binding protein 2 Human genes 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 229940079593 drug Drugs 0.000 claims 6
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 208000037819 metastatic cancer Diseases 0.000 claims 4
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 4
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 2
- 101001044927 Homo sapiens Insulin-like growth factor-binding protein 3 Proteins 0.000 claims 2
- 101000840572 Homo sapiens Insulin-like growth factor-binding protein 4 Proteins 0.000 claims 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims 2
- 102100022708 Insulin-like growth factor-binding protein 3 Human genes 0.000 claims 2
- 102100029224 Insulin-like growth factor-binding protein 4 Human genes 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 210000002889 endothelial cell Anatomy 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 230000001394 metastastic effect Effects 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161441738P | 2011-02-11 | 2011-02-11 | |
| US61/441,738 | 2011-02-11 | ||
| PCT/US2012/024697 WO2012109567A2 (en) | 2011-02-11 | 2012-02-10 | Treatment of angiogenesis disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017136730A Division JP6633029B2 (ja) | 2011-02-11 | 2017-07-13 | 血管新生障害の処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014507435A JP2014507435A (ja) | 2014-03-27 |
| JP2014507435A5 true JP2014507435A5 (enExample) | 2015-04-09 |
| JP6178241B2 JP6178241B2 (ja) | 2017-08-09 |
Family
ID=46639221
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013553604A Active JP6178241B2 (ja) | 2011-02-11 | 2012-02-10 | 血管新生障害の処置 |
| JP2017136730A Active JP6633029B2 (ja) | 2011-02-11 | 2017-07-13 | 血管新生障害の処置 |
| JP2019223678A Active JP7053559B2 (ja) | 2011-02-11 | 2019-12-11 | 血管新生障害の処置 |
| JP2022060499A Active JP7536049B2 (ja) | 2011-02-11 | 2022-03-31 | 血管新生障害の処置 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017136730A Active JP6633029B2 (ja) | 2011-02-11 | 2017-07-13 | 血管新生障害の処置 |
| JP2019223678A Active JP7053559B2 (ja) | 2011-02-11 | 2019-12-11 | 血管新生障害の処置 |
| JP2022060499A Active JP7536049B2 (ja) | 2011-02-11 | 2022-03-31 | 血管新生障害の処置 |
Country Status (7)
| Country | Link |
|---|---|
| US (6) | US8980261B2 (enExample) |
| EP (3) | EP2673363B1 (enExample) |
| JP (4) | JP6178241B2 (enExample) |
| CA (2) | CA2841404C (enExample) |
| DK (1) | DK2673363T3 (enExample) |
| ES (2) | ES2763087T3 (enExample) |
| WO (1) | WO2012109567A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2673363B1 (en) | 2011-02-11 | 2017-08-23 | The Rockefeller University | Treatment of angiogenesis disorders |
| TWI465241B (zh) * | 2012-12-19 | 2014-12-21 | Ind Tech Res Inst | 圓柏（Ｊｕｎｉｐｅｒｕｓ ｃｈｉｎｅｎｓｉｓ）萃取物或木酚素（ｌｉｇｎａｎ）用於製造抑制血管新生之藥物的用途 |
| HUP1300509A2 (hu) * | 2013-08-30 | 2015-03-30 | Gabor Firneisz | CXCL12 (Chemokine (C-X-C motif) Ligand 12) és IGFBP2 (Insulin-Like Growth Factor Binding Protein 2) gátlók cukorbetegséggel összefüggõ hasnyálmirigyrák kezelésénél történõ alkalmazásra |
| ES2688737A1 (es) * | 2017-05-04 | 2018-11-06 | Universidad Del País Vasco / Euskal Herriko Unibertsitatea | Método para diagnosticar placa ateroesclerótica inestable |
| JP7380670B2 (ja) * | 2018-07-17 | 2023-11-15 | ヘリックスミス カンパニー， リミテッド | Ｉｇｆ－１－暗号化ｄｎａ作製物及びｈｇｆ－暗号化ｄｎａ作製物を用いた神経病症治療 |
| MX2021010003A (es) * | 2019-02-26 | 2021-12-10 | Inspirna Inc | Anticuerpos anti-mertk de alta afinidad y usos de los mismos. |
| CN111808938A (zh) * | 2019-04-11 | 2020-10-23 | 南方医科大学南方医院 | Atp6v0d2用于动脉粥样硬化的早期诊断或疗效监控 |
| WO2023233715A1 (ja) | 2022-05-31 | 2023-12-07 | 吉野石膏株式会社 | 建物壁 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| ATE250673T1 (de) * | 1995-11-16 | 2003-10-15 | Baylor College Medicine | Verfahren zur identifizierung metastatischer sequenzen |
| EP1062340A2 (en) * | 1998-03-13 | 2000-12-27 | The Baylor College of Medicine | Compositions and methods for the treatment and prevention of metastatic disorders |
| US8257750B2 (en) | 1999-04-30 | 2012-09-04 | Kibow Biotech, Inc. | Calcium carbonate compositions for preventing or treating hyperphosphatemia |
| WO2000069454A1 (en) | 1999-05-17 | 2000-11-23 | Board Of Regents, The University Of Texas System | Suppression of endogenous igfbp-2 to inhibit cancer |
| US7196067B2 (en) * | 2000-09-14 | 2007-03-27 | The University Of British Columbia | Antisense insulin-like growth factor binding protein (IGFBP)-2-oligodeoxynucleotides for prostate and other endocrine tumor therapy |
| US20040018973A1 (en) * | 2002-01-25 | 2004-01-29 | University Of Pittsburgh | Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof |
| KR101212512B1 (ko) | 2002-08-21 | 2012-12-26 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브 |
| EP1644732B1 (en) | 2003-07-10 | 2010-02-24 | Central Institute For Experimental Animals | Animal model for the analysis of tumor metastasis |
| EP1709152A4 (en) * | 2003-12-15 | 2007-11-07 | Univ California | MOLECULAR SIGNATURE OF PTEN TUMOR SUPPRESSOR |
| FR2865736B1 (fr) | 2004-02-02 | 2006-07-14 | Synt Em | Inhibiteurs de l'angiogenese, compositions les contenant et leur utilisation pour le traitement des maladies liees a une deregulation de l'angiogenese |
| WO2006074292A2 (en) * | 2005-01-06 | 2006-07-13 | Aveo Pharmaceuticals, Inc. | Target validation assay |
| AU2006228989B2 (en) | 2005-03-30 | 2012-06-14 | Murdoch Childrens Research Institute | Methods and agents for modulating cellular activity |
| WO2007056604A2 (en) * | 2005-11-09 | 2007-05-18 | Irm Llc | Methods and compositions for modulating cell motility and inhibiting tumor metastasis |
| US9060961B2 (en) * | 2006-11-09 | 2015-06-23 | University Of Washington | Molecules and methods for treatment and detection of cancer |
| CA2705152C (en) | 2007-11-09 | 2016-10-11 | Peregrine Pharmaceuticals, Inc. | Anti-vegf antibody compositions and methods |
| WO2009082744A2 (en) | 2007-12-22 | 2009-07-02 | Sloan-Kettering Institute For Cancer Research | Prognosis and interference-mediated treatment of breast cancer |
| WO2009126650A2 (en) * | 2008-04-07 | 2009-10-15 | Cornell Research Foundation, Inc. | Inhibition of angiognesis |
| WO2009133141A2 (en) * | 2008-04-29 | 2009-11-05 | Pharnext | New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of angiogenesis |
| WO2009154790A2 (en) * | 2008-06-20 | 2009-12-23 | University Of Massachusetts | Novel metastasis suppresor genes and uses thereof |
| WO2010064702A1 (ja) * | 2008-12-05 | 2010-06-10 | 国立大学法人 東京大学 | 癌の予後を予測するためのバイオマーカー |
| WO2011011061A2 (en) * | 2009-07-21 | 2011-01-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method of regulating angiogenesis and lymphangiogenesis, and a pharmaceutical composition for effecting anti-angiogenic and anti-lymphangiogenic cancer therapy |
| EP2673363B1 (en) * | 2011-02-11 | 2017-08-23 | The Rockefeller University | Treatment of angiogenesis disorders |
-
2012
- 2012-02-10 EP EP12745124.3A patent/EP2673363B1/en active Active
- 2012-02-10 US US13/984,760 patent/US8980261B2/en active Active
- 2012-02-10 CA CA2841404A patent/CA2841404C/en active Active
- 2012-02-10 EP EP17184170.3A patent/EP3301176B1/en active Active
- 2012-02-10 CA CA3146962A patent/CA3146962A1/en active Pending
- 2012-02-10 JP JP2013553604A patent/JP6178241B2/ja active Active
- 2012-02-10 EP EP19191593.3A patent/EP3604534A1/en active Pending
- 2012-02-10 WO PCT/US2012/024697 patent/WO2012109567A2/en not_active Ceased
- 2012-02-10 ES ES17184170T patent/ES2763087T3/es active Active
- 2012-02-10 ES ES12745124.3T patent/ES2645366T3/es active Active
- 2012-02-10 DK DK12745124.3T patent/DK2673363T3/da active
-
2013
- 2013-08-09 US US13/963,657 patent/US8715660B2/en active Active
-
2015
- 2015-03-16 US US14/658,927 patent/US9493841B2/en active Active
-
2017
- 2017-06-22 US US15/629,971 patent/US10301684B2/en active Active
- 2017-07-13 JP JP2017136730A patent/JP6633029B2/ja active Active
-
2019
- 2019-05-17 US US16/415,472 patent/US10894989B2/en active Active
- 2019-12-11 JP JP2019223678A patent/JP7053559B2/ja active Active
-
2021
- 2021-01-04 US US17/140,409 patent/US12060619B2/en active Active
-
2022
- 2022-03-31 JP JP2022060499A patent/JP7536049B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014507435A5 (enExample) | ||
| JP2017508475A5 (enExample) | ||
| JP2016537383A5 (enExample) | ||
| PH12015501505B1 (en) | Antibodies that bind to tl1a and their uses | |
| EA201791093A1 (ru) | Антитела к cd47, способы и применение | |
| JP2013538057A5 (enExample) | ||
| MX2014008102A (es) | Inmunoglobulinas de dominio variable dual contra receptores. | |
| NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| EA201490053A1 (ru) | Антитела, которые связываются с ox40, и их применение | |
| EP2579895A4 (en) | ANTI-VEGF ANTIBODIES AND USES THEREOF | |
| WO2013173496A3 (en) | Cd33 antibodies and use of same to treat cancer | |
| MX369148B (es) | Agentes de unión kir3dl2. | |
| MX2010010387A (es) | Anticuerpos especificos para el complejo de bcr y metodos para el uso de los mismos. | |
| RU2017129721A (ru) | АНТИТЕЛА ПРОТИВ αβTCR | |
| WO2012135854A3 (en) | T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2 | |
| EA201270813A1 (ru) | АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ | |
| JP2014526898A5 (enExample) | ||
| WO2014012085A3 (en) | Bispecific asymmetric heterodimers comprising anti-cd3 constructs | |
| CO6612264A2 (es) | Proteinas terapeuticas de la union a dll 4 | |
| MX2021003636A (es) | Receptor antigenico quimerico. | |
| CN110869390A (zh) | 抗pd-l1抗体及其用途 | |
| PH12014501164A1 (en) | Anti-cd98 antibodies and methods of use thereof | |
| JP2013166763A5 (enExample) | ||
| CY1122132T1 (el) | Μεθοδοι για τη μειωση των ρυθμων εξαρσης του ασθματος με χρηση μπενραλιζουμαμπης | |
| CY1115349T1 (el) | Εξανθρωπισμενα αντι cxcr4 αντισωματα για τη θεραπεια καρκινου |